ODC1 and neoplasm: Previous clinical trials have tested the anti-tumor efficacy of α-difluoromethylornithine (DFMO, Eflornithine), an irreversible ODC inhibitor and FDA-approved drug for the treatment of Trypanosomiasis [24].